|
CYP21A2
|
55
disease terms (MeSH) has been reported with CYP21A2 gene.
|
[Click to re-sort the table]
|
|
|
Meta-analysis Publications
|
Adrenal Hyperplasia, Congenital
|
86
|
3
|
Hyperandrogenism
|
10
|
2
|
Polycystic Ovary Syndrome
|
6
|
1
|
Puberty, Precocious
|
5
|
0
|
Hirsutism
|
5
|
0
|
Virilism
|
4
|
1
|
Adrenal Gland Neoplasms
|
4
|
0
|
Hypertension
|
3
|
0
|
Autistic Disorder
|
2
|
0
|
Metabolism, Inborn Errors
|
2
|
0
|
Acne Vulgaris
|
2
|
0
|
Adenoma
|
2
|
0
|
Adrenal Rest Tumor
|
1
|
0
|
Thyroid Neoplasms
|
1
|
0
|
Arthritis, Rheumatoid
|
1
|
0
|
Atherosclerosis
|
1
|
0
|
Hyperplasia
|
1
|
0
|
Leukemia
|
1
|
1
|
Pregnancy Complications, Cardiovascular
|
1
|
0
|
Recurrence
|
1
|
0
|
Abortion, Spontaneous
|
1
|
0
|
Ehlers-Danlos Syndrome
|
1
|
0
|
Glioblastoma
|
1
|
0
|
Lymphoma, Follicular
|
1
|
0
|
Metabolic Syndrome X
|
1
|
0
|
Autoimmune Diseases
|
1
|
0
|
Diabetes Mellitus
|
1
|
0
|
Addison Disease
|
1
|
0
|
Asperger Syndrome
|
1
|
0
|
Fractures, Bone
|
1
|
0
|
Leukemia, Myeloid, Acute
|
1
|
1
|
Disorders of Sex Development
|
1
|
0
|
Hyperinsulinism
|
1
|
0
|
Mental Disorders
|
1
|
0
|
Opportunistic Infections
|
1
|
0
|
Oligomenorrhea
|
1
|
0
|
Alcoholism
|
1
|
0
|
Chagas Disease
|
1
|
0
|
Cystic Fibrosis
|
1
|
0
|
Infant, Premature, Diseases
|
1
|
0
|
Lymphoma, Non-Hodgkin
|
1
|
0
|
Meningioma
|
1
|
0
|
Breast Neoplasms
|
1
|
0
|
Stress, Psychological
|
1
|
0
|
Leprosy
|
1
|
0
|
Osteoporosis
|
1
|
0
|
Social Perception
|
1
|
0
|
Birth Weight
|
1
|
1
|
Chronic Disease
|
1
|
0
|
Glioma
|
1
|
0
|
Myelolipoma
|
1
|
0
|
Insulin Resistance
|
1
|
0
|
Meningeal Neoplasms
|
1
|
0
|
Psychiatric Status Rating Scales
|
1
|
0
|
Uniparental Disomy
|
1
|
0
|
Note: The number of publications displayed in this table will differ from the number displayed in the HuGE Literature Finder as the number
in Genopedia reflects only the indexed disease term without children terms, but the number in the HuGE Literature Finder
reflects all text searches of the disease term including the indexed term and corresponding children terms.
|
|
|